drugset / Trial / NCT00170690

Preference Study With Elderly Patients Recurrent Ovarian Cancer

NCT00170690

RandomizedParallel-groupOpen-labelTreatment

Summary

Comparison of the patient compliance treosulfan oral vs. intravenous (defined as end of therapy for the patient)

Timeline

Start
2004-08
Primary completion
2011-12
Completion
2012-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Treosulfan Small molecule 600 mg/m2 Oral
Subject Treosulfan Small molecule 7000 mg/m2 Oral

Indications